Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide

Toyotaka Iguchi, Kenji Yokoyama, Keisuke Miyamoto, Yoshinobu Aisa, Takayuki Shimizu, Takehiko Mori, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO). ATO was given intravenously at a dose of 0.15 mg/kg/day for 20 days, and the patient achieved complete remission. No serious adverse events related to ATO infusion were observed. He received ATO for 10 days as consolidation therapy and subsequently underwent HLA-matched unrelated donor stem cell transplantation. He remains in molecular remission 10 months after transplant. This case suggests that ATO could be a useful therapy prior to allogeneic stem cell transplantation in relapsed APL.

Original languageEnglish
Pages (from-to)75-77
Number of pages3
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume45
Issue number1
Publication statusPublished - 2004

Fingerprint

Unrelated Donors
Acute Promyelocytic Leukemia
Bone Marrow Transplantation
Stem Cell Transplantation
Therapeutics
Daunorubicin
Cytarabine
Tretinoin
arsenic trioxide
Transplants

Cite this

@article{9b9263d1742f44c9a4ec50ddbb222cf6,
title = "Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide",
abstract = "A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO). ATO was given intravenously at a dose of 0.15 mg/kg/day for 20 days, and the patient achieved complete remission. No serious adverse events related to ATO infusion were observed. He received ATO for 10 days as consolidation therapy and subsequently underwent HLA-matched unrelated donor stem cell transplantation. He remains in molecular remission 10 months after transplant. This case suggests that ATO could be a useful therapy prior to allogeneic stem cell transplantation in relapsed APL.",
author = "Toyotaka Iguchi and Kenji Yokoyama and Keisuke Miyamoto and Yoshinobu Aisa and Takayuki Shimizu and Takehiko Mori and Yasuo Ikeda and Shinichiro Okamoto",
year = "2004",
language = "English",
volume = "45",
pages = "75--77",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "1",

}

TY - JOUR

T1 - Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide

AU - Iguchi, Toyotaka

AU - Yokoyama, Kenji

AU - Miyamoto, Keisuke

AU - Aisa, Yoshinobu

AU - Shimizu, Takayuki

AU - Mori, Takehiko

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2004

Y1 - 2004

N2 - A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO). ATO was given intravenously at a dose of 0.15 mg/kg/day for 20 days, and the patient achieved complete remission. No serious adverse events related to ATO infusion were observed. He received ATO for 10 days as consolidation therapy and subsequently underwent HLA-matched unrelated donor stem cell transplantation. He remains in molecular remission 10 months after transplant. This case suggests that ATO could be a useful therapy prior to allogeneic stem cell transplantation in relapsed APL.

AB - A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO). ATO was given intravenously at a dose of 0.15 mg/kg/day for 20 days, and the patient achieved complete remission. No serious adverse events related to ATO infusion were observed. He received ATO for 10 days as consolidation therapy and subsequently underwent HLA-matched unrelated donor stem cell transplantation. He remains in molecular remission 10 months after transplant. This case suggests that ATO could be a useful therapy prior to allogeneic stem cell transplantation in relapsed APL.

UR - http://www.scopus.com/inward/record.url?scp=2142772519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142772519&partnerID=8YFLogxK

M3 - Article

C2 - 14999939

AN - SCOPUS:2142772519

VL - 45

SP - 75

EP - 77

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 1

ER -